These findings highlight the therapeutic potential of targeting MYCN S-nitrosylation to destabilize the cellular equilibrium essential for NEPC progression, offering a strategic avenue for reducing therapeutic resistance in this aggressive cancer phenotype. Here, MYCN is linked to cancer.